Trial
OCEAN(a)-Outcomes
Status Ongoing, primary completion March 2028
7,297 patients with established atherosclerotic cardiovascular disease and Lp(a) of 200 nmol/L or more, randomised to olpasiran 75 mg subcutaneously every 12 weeks or placebo; primary endpoint time to CHD death, MI or urgent coronary revascularisation. Started December 2022; ClinicalTrials.gov gives primary completion as 31 March 2028, and Amgen has pointed to a readout in 2026 to 2027.
Design. Double-blind, randomised, placebo-controlled, event-driven, multicentre; olpasiran, an N-acetylgalactosamine-conjugated siRNA that degrades LPA mRNA in hepatocytes, at the phase 2 dose that lowered Lp(a) by more than 95 percent (OCEAN(a)-DOSE, NEJM 2022).
Sister trials. OCEAN(a)-PreEvent (NCT07136012): 11,000 people at risk of a first major cardiovascular event, started August 2025, primary completion October 2031, the first primary-prevention outcomes trial for Lp(a). OCEAN(a)-Coronary imaging study (NCT07293260, n=406, started March 2026). Phase 2 extension: Lp(a) still 40 to 50 percent below baseline nearly a year after the last dose (JACC 2024).
olpasiranoutcomes trialphase 3secondary prevention
Page updated 17 August 2026.